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2Abstract
We show that IL-36R is expressed by T (CD4+ and CD8+) and B (CD19+)
lymphocytes in human blood and also by CD4+ T lymphocytes in the intestinal
lamina propria. IL-36R protein was mostly stored in the cytoplasm of CD4
lymphocytes and B cells, during steady andthe greatest expression of IL-36R mRNA
was measured in CD4+ (T helper) lymphocytesIL-36 β, which functions via IL-36R 
induced rapid and significant (P <0.05) proliferation of CD4+ lymphocytes, within
48h. IL-36R expression was also maintained on the surface of circulating CD4+
lymphocytes which enter the intestinal lamina propria.
In conclusion our study is the first to show that (1) all human blood lymphocytes
express IL-36R; (2) IL-36R expression is maintained by circulating CD4+
lymphocytes which enter the intestinal lamina propria and (3) IL-36R/IL-36 β induces 
rapid CD4 lymphocyte proliferation. The possible significance of these results in the
context of human disease is discussed.
31. Introduction
There are relatively few published studies regarding the biology of IL-36 receptor
(IL-36R) and its cytokine ligands IL-36α, IL-36β, IL-36γ and IL-36Ra, since this 
novel arm of the IL-1 family was discovered during the human genome project.
Fewer studies still have reported on the biological expression and function of these
molecules in human immune cells. There is now mounting evidence, from murine
studies, that the IL-36R/IL-36α axis may have an important role in skin disorders [1-
3]. This could also be the case in humans since missense mutations within IL-36RN
genes, which encode for IL-36RA, an IL-36R antagonist, have been shown to be
associated with pustular psoriasis [4]. In another study in which this association was
made, peripheral blood mononuclear cells, isolated from these patients produced high
concentrations of proinflammatory cytokines when cultured with IL-36α [5]. The 
expression of IL-36R by immune cells and the effect of IL-36 α-γ on these cells may 
also be important in the aetiology of many other inflammatory pathologies [reviewed
6]. Murine studies have shown that IL-36R is expressed on naive CD4+ Th cells and
that low concentration of IL-36 α-γ (100 ng/ml) directly induces proliferation of these 
cells [2].  In patients with psoriatic arthritis, both IL-36R and IL-36α expression is 
increased in the synovial lining and also in infiltrating CD 138+ plasma cells [7].
Although studies by Lamacchia et al., [8] have shown that the levels of expression of
IL-36R and IL-36α, in the synovium of collagen-induced arthritic mice, is not 
correlated with disease progression. Nevertheless, some of these studies do suggest
that IL-36R-expressing lymphocytes may proliferate in response to novel IL-36
cytokines and this may have some affect on inflammatory arthritis. If this is so then
IL-36R must also be expressed by cells entering the peripheral tissues from the blood.
4The aim of the study we report was to determine whether human lymphocytes express
IL-36R and if so to investigate the cellular distribution and biological significance of
this receptor.
2. Materials and methods
2.1. Reagents
Unless otherwise stated all laboratory reagents were purchased from Sigma, Poole,
UK and all antibodies were purchased from Serotec, Oxford, UK. Recombinant
human IL-36β proteins and murine anti-human IL-36R were supplied by the Amgen, 
Corporation, Seattle, Washington, USA. All reagents were measured for LPS
contamination by Amgen and University of Nottingham prior to use.
2.2. Bioethics
All studies were conducted following approval by local ethics committee following
written patient/participant consent.
2.3. Endotoxin assays
A chromogenic Limulus Amebocyte Lysate (LAL) assay (Kinetic-QCL,™Lonza,
USA) was performed on IL-1 reagents at Amgen and at the University of Nottingham
by standard methods. Assay sensitivity was between 0.005 and 50.0 EU/ml. All
reagents tested (IL-36R, IL-36β) contained <<0.05 Pg/ml LPS. As an additional test
for LPS contamination, THP1 monocytes (which are IL-36R negative but react to
LPS) were cultured with up to 500 ng/ml of IL-36R or IL-36β prior to measurement 
of TNF-α over a 24h period. All tests were shown to be negative for TNF α and, 
therefore, LPS at the concentrations used in the work described here.
52.4. Cell isolation and culture
2.4.1. Isolation of peripheral blood lymphocytes and cell sorting
Blood products from healthy donors were obtained from the National blood
transfusion service (Sheffield, UK). Isolation of peripheral blood mononuclear cells
(PBMC) was performed using differential centrifugation in histopaque 1077 (Sigma-
Aldirich, UK) by standard methods. The isolated PBMC were incubated with
magnetic microbeads conjugated with mouse anti-human CD19+, anti-human CD4+,
CD3+ or anti-human CD8+ antibodies (Miltenyi Biotec, Bisley, UK) for 20 min at 6ºC.
The labeled cells were separated by passing the cell suspension over a magnetic-
activated cell sorter (AutoMACS, Miltenyi Biotec, Germany). Each population was
carefully removed from the columns and were separately kept in culture in RPMI
1640 media supplemented with 10% (v/v) Fetal Calf Serum, 200mM L-glutamine and
5 mL of antibiotic solution containing 100 IU of penicillin and 1mg of streptomycin
per mL (Sigma-Aldirich, UK).
2.4.2. Isolation of human ileal lamina propria cells
Fresh, histologically normal mucosal samples, surplus to clinical requirements, were
obtained from human terminal ileum resected (as part of right hemicolectomy
specimens) for tumour. Ethical committee approval was provided by the Nottingham
Research Ethics Committee. Mucosal samples were obtained at least 5 cm from the
tumour. The mucosal samples were washed thoroughly with calcium- and
magnesium-free Hanks balances salt solution (HBSS; Gibco BRL, Gaithesburg, MD,
USA), to remove adherent luminal material. Lamina propria cells were isolated from
mucosal samples using a previously described technique [9].
6Briefly, dissected strips of mucosa were weighed and incubated in 1 mmol/l
dithiothreitol solution (DTT) (Sigma, Poole, Dorset, UK) for 20 minutes at room
temperature. To remove the epithelial cells, mucosal strips were treated three times
with 1 mmol/l ethylenediamine tetra-acetic acid (BDH, Poole, Dorset, UK) at 37°C
for 30 min. Between each incubation step the strips were washed with calcium and
magnesium-free HBSS.
The mucosal samples, denuded of epithelial cells, were subsequently cultured at 37 0C
in RPMI containing 10% fetal calf serum (Gibco) in 60 mm tissue culture dishes
(Costar Corp, Cambridge, MA, USA). During culture, cells appeared both in
suspension and attached to the tissue culture dishes. After a 24h culture period, these
cells were collected by transferring the pieces of mucosal tissue to culture dishes
containing fresh media and incubating the original dishes (containing cells only) at
40C for 60 min. Following pippeting to detach adherent cell, the cells were counted
and viability tested using Trypan blue (4 μg/ml) and were found to be between 90-
100% viable.
Depending on down-stream applications, the isolated lamina propria cells were
suspended in appropriate medium at a density of 1x106 cells/ml. To stabilize RNA
prior to extraction, samples for qRT-PCR analysis were immediately pelleted and
suspended in RNAlater RNA Stabilization Reagent according to the Manufacturer’s
recommendations (QIAGEN, Crawley UK). Total RNA was extracted from the cells,
reverse-transcribed into cDNA and amplified in a typical real time PCR reaction. A
relative quantification analysis using GAPDH as the reference gene and IL-36R as the
target gene was performed on a LightCycler® 480 analyser. HT 29 cells and THP-1
cells were used as positive and negative controls respectively. FACS analyses were
also performed on migrated cells to ascertain overall CD3+ population, CD4+
7population within the CD3+ populations and expression of IL-36R protein by CD4+
cells. Each analysis was performed in triplicate on 5 separate occasions.
2.4.3. HT 29 cell cultures
The human colonic epithelial carcinoma cell line, HT-29 (was a kind gift from
Professor Susan Watson, University of Nottingham) was used as a positive control for
IL-36R expression, as previously reported [10] Cells were cultured in Dulbecco's
modified Eagle's medium supplemented with glucose (25mM), Sodium Bicarbonate
(44mM), Transferrin (10mg/l), sodium pyruvate (1mM), L-glutamine (2mM), 0.1 mM
non-essential amino acids (NEAA) and 10% FCS. Cell cultures were maintained in
humidified incubators at 37°C, 5% CO2. The medium was changed every day to
prevent glucose exhaustion.
2.5. Flow Cytometry
Following cell sorting, FACS analyses were performed by standard methods. Briefly,
1×106 test cells of each purified cell population (CD19+, CD4+ and CD8+) were
resuspended in FACS buffer (BSA 1% w/v); EDTA (2 mM). The cells were blocked
in FACS buffer containing human serum (10% v/v) for 15 min and some cell
preparations were permeabilized with 10% (w/v) Saponin (Sigma-Aldirich, UK).
Permeabilized and non-permeabilized cells were incubated for 45min with mouse
anti-human IL-36R antibody (Amgen, USA) or with IgG2a isotype control conjugated
with FITC for negative controls (Abcam, UK). Cells were then analysed using an
FACSCanto II analyser (Becton Dickinson, USA). Samples were acquired using the
CellQuest pro software (Becton Dickinson) and analysed using the WinMDI 2.8
8software. Cell viability was assessed by propidium iodide uptake (20 µg/mL for 10
min) via FACS analysis and was found to be >90% in all cases.
2.6. Analysis of IL-36R expression
2.6.1 Analayis of IL-36R mRNA expression by quantitative real time RT-PCR
(qRT-PCR in real time)
Prior to qRT-PCR analysis, RNA was first reverse-transcribed into cDNA in a reverse
transcription (RT) reaction using the Transcriptor First Strand cDNA Synthesis Kit
(Roche, West Sussex, UK) as per supplier’s instructions. A random hexamer primer
was used as detailed in the manufacturer manual. The total reaction volume was 20 μl 
made up of Transcriptor Reverse Transcriptase reaction buffer (4 μl), 
Deoxynucleotide (dNTP) mix (2 μl), random hexamer primer (2 μl), protector RNase 
inhibitor (0.5 μl), Transcriptor Reverse transcriptase (0.5 μl) and a maximum of 11 μl 
RNA (up to 1μg of total RNA was used). The following program was used on the 
thermal cycler: 10 minutes at 25oC, 30 minutes at 55oC, 5 minutes at 85oC then hold
at 4oC. All samples were run in duplicate.
 For qRT-PCR, a reaction volume of 25 μl was used on the LightCycler® 480 
analyser (Roche, West Sussex, UK). This consisted of 12.5 μl LightCycler® 480 
Probes Master (2x concentration), 2 μl cDNA, 1.5 μl forward primer, 4.5 μl reverse 
primer (Table1), 0.88 μl hydrolysis probe (Universal Probe Library, Roche, West 
Sussex, UK) and 3.63 μl PCR-grade water. The working concentration for all primers 
and probes was 0.5 μM. The expression of the IL-36R gene was normalized to the 
expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) through relative
quantification using the 2-ΔΔCT method [11]. THP-1 cells were used as a negative
control and HT29 cells were used as positive controls for IL-36R expression. Primer
9sequences are shown in table 1and as previously reported [12-13] and PCR product
obtained was also shown to be of correct size as that previously reported [12].
2.6.2. Analysis of IL-36R protein expression by immunocytochemistry
An aliquot of approximately 103 purified CD4+, CD8+ and CD19+ cells was separately
collected from cell culture, washed in 1mL of PBS and centrifuged at 250 g for 5 min.
Cells were suspended in 500µL of PBS and centrifuged at 800rpm in the CytoSpin 4
(ThermoScientific, UK) to lay the cells in the slides. Initially the cells were fixed on
ice cold solution of acetone and methanol 1:1 (v/v) for 2 min and the slides were
washed for 10 min in PBS. Cells were incubated for 20 min at RT with 10% (v/v)
human serum (Sigma Aldrich, UK) to block unspecific binding. Slides were then
incubated for 1h at RT with mouse anti-human IL-36R (25µg/mL, Amgen, Seattle,
WA, USA) and incubated for 1h at RT with goat anti-mouse IgG1 conjugated with
fluorescein isothiocyanate (FITC). Slides were rinsed with PBS and incubated for
20min with Phallodin-Rhodamine (200ng/mL, P1951, Sigma-Aldirich, UK). The
cells were washed and mounted with Prolong Gold anti-fade reagent containing 4',6-
diamidino-2-phenylindole (DAPI, Invitrogen, Paisley, UK). The detection of IL-36R
was compared with negative control cells, incubated without the primary antibody.
2.7. Lymphocyte proliferation assays
A standard WST-1 cell proliferation assay (Roche Diagnostics Ltd., West Sussex, UK)
was used (as per manufacturer’s instructions) to measure proliferation of lymphocytes
(104 cells/100μl RPMI medium) after 48h culture  in IL-36β (100 ng/ml). We deliberately 
used a very short culture period to ascertain true proliferation rather than increased
survival which was shown to be problematic in other studies. Results from the
colourimetric assay were compared by measuring absorbance at 450 nm on a Labtech LT-
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4000 ELISA Plate Reader and to assess mitochondrial enzyme activity, these were
compared to a standard curve obtained from control lymphocytes. Lymphocytes cultured
with Concanavalin A (conA) (75μg/ml) over the same time period were used as a positive 
control while unstimulated lymphocytes were used as a negative control.
2.8. Statistical Analysis
An ANOVA test with a one way classification was used to determine significant
differences, at the 95% confident interval, in the numbers of lymphocytes which had
divided after 24h. A post-hoc test (Tukey’s) was then used to identify means which
were significant. Statistical data was analysed using SPSS software, licenced to the
University of Nottingham.
3. Results
Initially we investigated IL-36R expression in non-adherent cells in blood buffy coats
and found this to be positive (above that expressed by the positive control, HT-29
cells). We then found that most of the IL-36R signal was coming from the CD3+ (pan
T cell) fraction (Fig 1). When we examined IL-36R expression in the granulocyte
fraction (below the buffy coat) we found that these cells did not express the receptor
and was comparable to the negative control cell line (THP1) (Fig 1). The next set of
experiments investigated IL-36R mRNA expression in blood lymphocyte subsets
compared with HT29 cells (positive control). Quantitative PCR analysis showed that
in all lymphocyte subsets, constitutive IL-36R mRNA expression was greater than
that measured in HT29 cells but this increase was significant (P <0.05) only in CD4+
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T cells (Fig 2A). We then incubated CD4+ lymphocytes with varying concentrations
of IL-36β, to ascertain whether this would alter IL-36R expression relative to 
constitutive levels. Our results showed that all concentrations of cytokine (10-500
ng/ml) significantly increased IL-36R expression above constitutive levels but this
was greatest at 100-200 ng, at which there was a plateau in IL-36R mRNA expression
(Fig 2B).
We then used fluorescent microscopy to investigate the cellular distribution of IL-
36R in lymphocytes. IL-36R immunoreactivity was detected on the cell membranes of
CD4+ and CD8+ T lymphocytes as well CD19+ B lymphocytes (Fig 3). In all cases
the immunoreactivity was comparable to that observed in HT29 cells (Fig 3 panel B)
which have previously been used as an IL-36R positive control. In contrast, a negative
control panel (without IL-36R antibody and secondary antibody only) showed no non-
specific binding to these cells (control overlay D). However, this study also showed
what appeared to be cytoplasmic localisation of IL-36R in both CD4+ and CD19+
lymphocytes, as well as HT29 cells but this was much less clear in CD8+
lymphocytes (Fig 3 panel B). To further investigate both expression and localisation
of IL-36R protein, we used FACS analysis on non-permeabilised (cell membrane
only) and permeabilised (cell membrane and cytoplasm) cells. Our results show that
most of the measured IL-36R protein in CD4+ cells was within the cell cytoplasm
with an associated increased shift in IL-36R compared with non-permeabilised cells
(Fig 4A). In contrast to CD4+ lymphocytes, the levels of IL-36R protein detected in
CD8+ lymphocytes was comparable in both permeabiled and non-permeabiled cells,
implying that most expression was membrane associated (Fig 4B). In both CD19+ B
lymphocytes (Fig 4C) and in HT29 cells (Fig 4D) IL-36R protein expression was
increased in permeabilised cells but the associated shifts between IL-36R protein
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expression in permeabilised and non-permeabilised cells was not as large as that
measured in CD4+ lymphocytes. To investigate whether ligation of IL-36R had any
physiological effect on CD4+ lymphocytes, we measured lymphocyte proliferation
after culturing the cells with IL-36β for 48h.  Our studies showed that CD8+ T 
lymphocytes and CD19+ B lymphocytes did increase in number in cultures exposed
to IL-36β but this change was not statistically significant. However, IL-36β did 
induce CD4+ T lymphocytes to proliferate at significantly higher (P < 0.05) numbers
than unstimulated controls (Fig 5). In all cases, proliferation was low, probably due
to the short culture period used.
The dynamic circulation of immune cells from blood into tissues can have profound
effects on the expression of numerous proteins. With this in mind, we then
investigated whether expression of IL-36R was maintained, lost or reduced when
CD4+ lymphocytes enter peripheral tissues. We chose surgically resected (normal)
human intestinal mucosal tissues for this analysis. Initially (following cellular
isolation from the lamina propria; LP) we measured the population of CD3+ (pan T
cells) lymphocytes and within this population the number of CD4+ cells, to ascertain
whether CD4+ cells were a good representative population to study (i.e in sufficient
numbers within the tissues. Our results show that 75% of cells which migrated from
the LP tissues were CD3+ (Fig 6A & B) and of these, 55% were CD4+ (Fig 6C & D).
We then measured IL-36R mRNA expression in isolated intestinal LP cells by qPCR
and compared this to expression by HT29 cells (positive control) and THP1
monocytes (negative control). This showed that LP cells expressed IL-36R at higher
levels than HT29 cells (Fig 7A) and when we further analysed the CD4+ sub-
population within the total isolated LP population (by FACS analysis) we found that
they expressed IL-36R on their cell membranes (Fig 7B).
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4. Discussion
The study we report is the first to show that human blood lymphocytes express the
novel IL-1 family cytokine receptor IL-36R. The study therefore shows differences in
the expression of IL-36R between humans and mice. In mice IL-36R has been
reported to be expressed by splenic CD4+ T lymphocytes but not by CD8+ T
lymphocytes or B lymphocytes [2]. Our study also differs from that of Foster et al.,
[14] which reports a lack of expression of IL-36R in human lymphocytes. It is
possible that that some anomalies have arisen due to differences in this study and ours.
We have used three different methods to show expression of IL-36R mRNA and
protein in human Th cells, CTLs and B lymphocytes. In our studies all reagents were
LPS tested and the IL-36R antibody used was monoclonal, unlike the polyclonal
antibody used in the aforementioned study. We also used the same PCR probe we
successfully reported on before [12-13] and visualised the PCR product, using an
agarose gel, which was found to be the correct size for IL-36R (data not shown). Our
data shows differences in the expression pattern of IL-36R in different lymphocytes,
with CD4+ lymphocytes (and to a lesser extent B lymphocytes) containing large
cytoplasmic stores of the receptor, whereas in CD8+ lymphocytes most of the IL-36R
protein is found on the cell membrane. We then studied whether, or not, IL-36 β
altered expression of IL-36R in CD4+ lymphocytes and found that IL-36R expression
plateaued when the cells were incubated with 100-200 ng/ml IL-36β. Human IL-36α-
γ have been shown before to be effective at relatively low doses, when compared to 
murine homologues [12-13]. The current study is, therefore, consistent with the latter
since culture of CD4+ cells with IL-1β at 500 ng/ml decreased IL-36R expression, 
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when compared to expression at 100-200 ng/ml, which also indicates a negative
feedback loop shown in a previous paper [12].
Classic IL-1 cytokines are known to indirectly induce T cell proliferation by
enhancing APC maturation and survival[15-16] and we have recently shown that this
is also the case for IL-36β and IL-36γ-stimulated human monocyte derived dendritic 
cells (MDDCs) [12]. Few studies have reported the direct effect of classic IL-1
cytokines on lymphocyte proliferation. However, Ben-Sasson et al., [17] have shown
that antigen-primed murine CD4+, Th cells proliferate in response to IL-1β. In this 
study, CFSE analysis showed that IL-1β stimulation was responsible for only about a 
2 fold increase in CD4+ Th cells and that the overall 7-8 fold increase measured at the
end of the experiments was mostly due to enhanced survival of IL-1β-stimulated Th 
cells. Similarly, IL-1β has also been shown to induce the proliferation of human IL-17 
producing, CD4+ Th cells [18] and IL-17/Th memory cell populations [19]. Due to
measuring proliferation after only 48h, our studies show that there is a rapid effect of
IL-36β which cannot be due merely to increased survival as has been shown in some 
other studies mentioned above. However, the down-side to using a short incubation
period was that quite low numbers of cells had proliferated and also we cannot say if
CTL or B cell proliferation may have surpassed that of CD4+ lymphocytes after a
longer period of time. Nevertheless the study did show some functionality of this
receptor in CD4+ lymphocytes.
If expression of IL-36R by lymphocytes has some functional significance in disease
within peripheral tissues, then expression of IL-36R must be maintained on the cell
membrane of lymphocytes as they enter the tissues from circulation. We found that
IL-36R mRNA was expressed in the lamina propria at higher levels than was
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expressed by HT-29 (positive) cells. Intestinal samples were then denuded of
epithelium and cultured to allow migration of cells from the LP. Consistent with a
previous study [9], 75% of the cells which migrated from the LP, after 36h, were
CD3+ T cells and of these 55% expressed CD4. However, we show for the first time
that the CD4+ population within the LP also expressed IL-36R. Usually γδ T cells, 
which reside in the intestine, do not express CD4 [20] but rare γδ/CD4+ T phenotypes 
have been shown to be expanded in patients with rare genetic disorders  such as CD3δ 
deficiency, a form of severe combined immunodeficiency [21]. Intra-epithelial
lymphocyte populations are known to increase in patients with various intestinal
disorders [22] but the model we have used denudes the intestinal epithelium which
would also preclude intra-epithelial lymphocytes from the CD4/IL-36-R population
we have measured. Our results, therefore, most likely indicate that CD4+
lymphocytes maintain IL-36R expression as they enter peripheral tissue from the
blood. Thus, expression of IL-36R by CD4+ lymphocytes, and their activation via
IL-36R cytokine ligands, could have a role in human intestinal and blood disorders.
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Figure Legends
Table 1. Primer sequences and probe numbers for the quantification of the gene
expression.
Primer sequenes and probes numbers are shown for IL-36R gene and the reference
gene GADPH. Acc= GenBank accession number.
Figure 1. IL-36R mRNA is expressed by non-adherent and CD3+ cells within
human blood buffy coats.
Quantitative PCR analysis was used to show IL-36R expression in blood cells,
relative to HT-29 (positive) cells which were given the arbitrary value of 1. IL-36R
was detected in the non-adherent cells of the buffy coat and within this population
most expression was detected in CD3+ lymphocytes (T cells). Expression of IL-36R
was not detected in blood granulocytes, which may have contaminated the buffy coat,
or in THP1 cells used as a negative control. Asterisk denotes significant increase (p =
0.05) in mRNA expression above that measured in HT-29 cells. Error bars show
standard deviation from the mean. Each experiment was performed in triplicate on 5
separate occasions.
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Figure 2. IL-36R mRNA is expressed by human blood lymphocytes and is dose-
dependently increased by IL-36β in CD4+ cells  
(A) Quantitative PCR analysis showing IL-36R expression in T and B lymphocytes
relative to HT-29 (positive) cells (not shown). (B) Expression of IL-36R mRNA is
dose-dependently and significantly increased in CD4+ lymphocytes by IL-36β but 
plateaus between 100-200 ng/ml. Asterisk denotes significant increase (p = 0.05) in
mRNA expression above that measured in HT-29 cells (A) or unstimulated CD4+
lymphocytes (B). Error bars show standard deviation from the mean. Each experiment
was replicated 3 times on 5 separate occasions.
Figure 3. Localisation of IL-36R by immuno-fluorescence in the cytoplasm and
cell membrane of CD4+ and CD8+ T lymphocytes and CD19+ B lymphocytes in
human blood.
Each panel shows immunofluorecent images of (A) cell nuclei (stained with DAPI);
(B) IL-36R isolated by mouse ant-human IL-36R and secondary anti-mouse/FITC on
the cell membrane (open arrows) and cytoplasm (closed arrows); (C) β-actin (stained 
with Phalloidin) and (D) shows overlay images taken from control cells (secondary
anti-mouse FITC antibody only) with no FITC signal detected. Each panel is
representative of 3 replicates isolated on 5 separate occasions. Scale bar (bottom left)
= 10 μM.  
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Figure 4. IL-36R is expressed in the cytoplasm and cell membranes of T and B
lymphocytes isolated from human blood
FACS histograms showing the expression of IL-36R on the cell membranes (non-
permeabilised cells) and cytoplasm (permeabilised cells) relative to isotype controls.
(A) CD4+ T helper cells; (B) CD8+ cytotoxic T lymphocytes; (C) CD19+ B
lymphocytes and (E) HT-29 (positive) cells. All FACS plots are representative of 3
replicate plots per group performed on at least 3 separate occasions.
Figure 5. IL-36β induces early proliferation of IL-36R expressing CD4+ T helper 
cells.
Lymphocyte subsets were aliquoted into 96 well plates at a concentration of 104 cells
per 100 μl RPMI, containing 100 ng/ml IL-36β.  For each subset additional well 
contained lymphocytes in RPMI only (negative control) and lymphocytes in media
containing conA (75 μg/ml). After 48 h culture the numbers of lymphocytes were 
enumerated using a WST-1 cell proliferation assay, read at 450 nm. The optical density
measured in each sample was then compared to the optical density obtained from
standard curves of each lymphocyte subset ranging from 103-106 cells. Asterisk denotes a
significant increase (p = 0.05) in lymphocyte numbers compared with the number of
cells in the unstimulated population. The data shows a mean from 3 replicates
performed on 3 separate occasions.
24
Figure 6. Percentage of CD3+ and CD4+ lymphocytes migrating into human LP.
FACS analyses were performed on cells, which had migrated from the LP, to
ascertain; (A) Expression of CD3 (compared with isotype control) within the LP cell
population; (B) Percentage of CD3+ cell population as a total of migrated LP cells;
(C) Expression of CD4 (compared with isotype control) within the LP cell population;
(D) Percentage of cells expressing CD4 within the CD3+ population. Each FACS
histogram is representative of 3 replicates performed on 5 separate occasions.
Figure 7. IL-36R is expressed by CD4+ lymphocytes migrating into human LP.
(A) Quantitative PCR analysis was used to show IL-36R mRNA expression in
migrated LP cells, relative to HT-29 (positive) cells which were given the arbitrary
value of 1. IL-36R was detected in LP cells at a higher level than in HT-29 cells. In
comparison, no expression was of IL-36R was detected in THP1 cells. (B) CD4+
lymphocytes within the LP population express IL-36R protein, shown relative to the
isotype control. Asterisk denotes significant increase (p = 0.05) in mRNA expression
above that measured in HT-29 cells. Error bars show standard deviation from the
mean. Each experiment was replicated 3 times on 5 separate occasions.
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